Loading...

Steven Edelman

TitleRecall Hcomp
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0912
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    KINETICS OF IN VIVO GLUCOSE UPTAKE IN DIABETES
    NIH/NIDDK F32DK008271Apr 15, 1989
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pettus J, Santos Cavaiola T, Edelman SV. Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. Diabetes Technol Ther. 2018 Jun; 20(6):448-451. PMID: 29901406.
      View in: PubMed
    2. Dolinar R, Lavernia F, Edelman S. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN. Endocr Pract. 2018 Feb; 24(2):195-204. PMID: 29466056.
      View in: PubMed
    3. Edelman SV, Polonsky WH. Response to Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425-1432. Diabetes Care. 2018 Feb; 41(2):e18. PMID: 29358472.
      View in: PubMed
    4. Edelman SV. Taking Control Of Your Diabetes: An Innovative Approach to Improving Diabetes Care Through Educating, Motivating, and Making the Connection Between Patients and Health Care Providers. Clin Diabetes. 2017 Dec; 35(5):333-339. PMID: 29263578.
      View in: PubMed
    5. Edelman SV. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists. J Fam Pract. 2017 Oct; 66(10 Suppl):S12-S16. PMID: 28991932.
      View in: PubMed
    6. Berard L, Bonnemaire M, Mical M, Edelman S. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey. Diabetes Obes Metab. 2018 Feb; 20(2):301-308. PMID: 28719066.
      View in: PubMed
    7. Edelman SV, Polonsky WH. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care. 2017 11; 40(11):1425-1432. PMID: 28801473.
      View in: PubMed
    8. Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Diabetes Care. 2017 11; 40(11):1469-1478. PMID: 28801475.
      View in: PubMed
    9. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017 Aug; 8(4):863-873. PMID: 28646411.
      View in: PubMed
    10. Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient. 2017 Jun; 10(3):321-334. PMID: 27981439.
      View in: PubMed
    11. Edelman SV, Hollander PA, Wright EE. Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes. Am J Med. 2017 05; 130(5):614. PMID: 28431671.
      View in: PubMed
    12. Polonsky WH, Capehorn M, Belton A, Down S, Alzaid A, Gamerman V, Nagel F, Lee J, Edelman S. Physician-patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study. Diabetes Res Clin Pract. 2017 May; 127:265-274. PMID: 28407552.
      View in: PubMed
    13. Hirsch JD, Bounthavong M, Arjmand A, Ha DR, Cadiz CL, Zimmerman A, Ourth H, Morreale AP, Edelman SV, Morello CM. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic. J Manag Care Spec Pharm. 2017 Mar; 23(3):318-326. PMID: 28230459.
      View in: PubMed
    14. Heinemann L, Fritz I, Khatami H, Edelman SV. Administration of Biosimilar Insulin Analogs: Role of Devices. Diabetes Technol Ther. 2017 02; 19(2):79-84. PMID: 28118050.
      View in: PubMed
    15. Polonsky WH, Fisher L, Hessler D, Edelman SV. Investigating Hypoglycemic Confidence in Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2017 02; 19(2):131-136. PMID: 27997217.
      View in: PubMed
    16. Edelman SV. Regulation Catches Up to Reality. J Diabetes Sci Technol. 2017 01; 11(1):160-164. PMID: 27630249.
      View in: PubMed
    17. Pettus J, Edelman SV. Differences in Use of Glucose Rate of Change (ROC) Arrows to Adjust Insulin Therapy Among Individuals With Type 1 and Type 2 Diabetes Who Use Continuous Glucose Monitoring (CGM). J Diabetes Sci Technol. 2016 09; 10(5):1087-93. PMID: 27044518.
      View in: PubMed
    18. Pettus J, Edelman SV. Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes. J Diabetes Sci Technol. 2017 01; 11(1):138-147. PMID: 27530720.
      View in: PubMed
    19. McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T. Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need? Adv Ther. 2016 Aug; 33(8):1267-78. PMID: 27384191.
      View in: PubMed
    20. Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A. Improvement of Insulin Injection Technique: Examination of Current Issues and Recommendations. Diabetes Educ. 2016 08; 42(4):379-94. PMID: 27216036.
      View in: PubMed
    21. Ahn D, Pettus J, Edelman S. Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes. J Diabetes Sci Technol. 2016 05; 10(3):793-8. PMID: 26884422.
      View in: PubMed
    22. Pettus J, Edelman SV. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technol Ther. 2016 Feb; 18 Suppl 2:S234-42. PMID: 26784128; PMCID: PMC4717500.
      View in: PubMed, PubMed Central
    23. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016 09; 32(6):478-96. PMID: 26509843.
      View in: PubMed
    24. Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD. Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients. Ann Pharmacother. 2016 Jan; 50(1):8-16. PMID: 26546580.
      View in: PubMed
    25. Peters AL, Pollom RD, Zielonka JS, Carey MA, Edelman SV. BIOSIMILARS AND NEW INSULIN VERSIONS. Endocr Pract. 2015 Dec; 21(12):1387-94. PMID: 26340139.
      View in: PubMed
    26. Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2015 Nov; 17(11):773-9. PMID: 26167948.
      View in: PubMed
    27. Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of Life. Diabetes Technol Ther. 2015 Sep; 17(9):657-63. PMID: 25923812.
      View in: PubMed
    28. Pettus J, Price DA, Edelman SV. HOW PATIENTS WITH TYPE 1 DIABETES TRANSLATE CONTINUOUS GLUCOSE MONITORING DATA INTO DIABETES MANAGEMENT DECISIONS. Endocr Pract. 2015 Jun; 21(6):613-20. PMID: 25716635.
      View in: PubMed
    29. Edelman SV. Comment on Little et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114-2122. Diabetes Care. 2014 Dec; 37(12):e270-1. PMID: 25414404.
      View in: PubMed
    30. Edelman SV, Liu R, Johnson J, Glass LC. Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140. Diabetes Care. 2014 Dec; 37(12):e263-4. PMID: 25414399.
      View in: PubMed
    31. David G, Gill M, Gunnarsson C, Shafiroff J, Edelman S. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes. Am J Manag Care. 2014 Nov 01; 20(11):e490-7. PMID: 25730348.
      View in: PubMed
    32. Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014 Oct; 127(10 Suppl):S11-6. PMID: 25282008.
      View in: PubMed
    33. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015 Mar; 38(3):412-9. PMID: 25271207.
      View in: PubMed
    34. Sarikonda G, Sachithanantham S, Pettus J, Rodriguez-Calvo T, Phatak S, Edelman S, von Herrath M. Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects. Clin Immunol. 2014 Nov; 155(1):27-9. PMID: 25173803.
      View in: PubMed
    35. Edelman S, Polonsky WH, Parkin CG. Biosimilar insulins are coming: what they are, what you need to know. Curr Med Res Opin. 2014 Nov; 30(11):2217-22. PMID: 25105307.
      View in: PubMed
    36. Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014 Aug 01; 36(8):1275-89. PMID: 25044021.
      View in: PubMed
    37. Pettus J, Stenger P, Schachner HC, Dunne N, Parkes JL, Pardo S, Edelman SV. Testing versus guessing blood glucose values: impact on self-care behaviors in type 2 diabetes. Curr Med Res Opin. 2014 Sep; 30(9):1795-802. PMID: 24889281.
      View in: PubMed
    38. Blumer I, Edelman S. Biosimilar insulins are coming: the top 10 things you should know. Postgrad Med. 2014 May; 126(3):107-10. PMID: 24918796.
      View in: PubMed
    39. Edelman SV, Liu R, Johnson J, Glass LC. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2132-40. PMID: 24742662.
      View in: PubMed
    40. Edelman SV, Blose JS. The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 Diabetes. Diabetes Educ. 2014 05; 40(3):269-279. PMID: 24695260.
      View in: PubMed
    41. Dolinar RO, Edelman S, Heinemann L, Home P, Goyal S, Polonsky WH, Schellekens H. Impact of Biosimilar Insulins on Clinical Practice: Meeting Report. J Diabetes Sci Technol. 2014 Jan; 8(1):179-185. PMID: 24876554.
      View in: PubMed
    42. Stauder U, Enginee D, Elton H, Penfornis A, Edelman S. Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study. J Diabetes Sci Technol. 2014 Jan; 8(1):123-131. PMID: 24876548.
      View in: PubMed
    43. Sarikonda G, Pettus J, Phatak S, Sachithanantham S, Miller JF, Wesley JD, Cadag E, Chae J, Ganesan L, Mallios R, Edelman S, Peters B, von Herrath M. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun. 2014 May; 50:77-82. PMID: 24387802.
      View in: PubMed
    44. Sarikonda G, Pettus J, Sachithanantham S, Phatak S, Miller JF, Ganesan L, Chae J, Mallios R, Edelman S, Peters B, von Herrath M. Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One. 2013; 8(11):e79383. PMID: 24223938; PMCID: PMC3817042.
      View in: PubMed, PubMed Central
    45. Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am. 2013 Dec; 42(4):809-32. PMID: 24286951.
      View in: PubMed
    46. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013 May; 125(3):136-44. PMID: 23748514.
      View in: PubMed
    47. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol. 2013 Dec; 149(3):317-23. PMID: 23643354.
      View in: PubMed
    48. Edelman S, Bhoyrul S, Billy H, Cornell C, Okerson T. Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric banding. Postgrad Med. 2012 Nov; 124(6):73-81. PMID: 23322140.
      View in: PubMed
    49. Hirsch IB, Amiel SA, Blumer IR, Bode BW, Edelman SV, Seley JJ, Verderese CA, Kilpatrick ES. Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. Diabetes Technol Ther. 2012 Nov; 14(11):973-83; quiz 983. PMID: 23066850.
      View in: PubMed
    50. Blumer I, Edelman SV, Hirsch IB. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012 Jul 26; 367(4):383; author reply 383-4. PMID: 22830479.
      View in: PubMed
    51. Polonsky WH, Fisher L, Hessler D, Edelman SV. A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed? Curr Med Res Opin. 2011 Nov; 27 Suppl 3:31-7. PMID: 22106976.
      View in: PubMed
    52. Frias JP, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Edelman SV. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol. 2011 Jul 01; 5(4):887-93. PMID: 21880230; PMCID: PMC3192594.
      View in: PubMed, PubMed Central
    53. Villa-Caballero L, Morello CM, Chynoweth ME, Prieto-Rosinol A, Polonsky WH, Palinkas LA, Edelman SV. Ethnic differences in complementary and alternative medicine use among patients with diabetes. Complement Ther Med. 2010 Dec; 18(6):241-8. PMID: 21130360; PMCID: PMC3003303.
      View in: PubMed, PubMed Central
    54. Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 2010 Oct 21; 5:23-37. PMID: 21042540; PMCID: PMC2963920.
      View in: PubMed, PubMed Central
    55. Polonsky WH, Fisher L, Guzman S, Sieber WJ, Philis-Tsimikas A, Edelman SV. Are patients' initial experiences at the diagnosis of type 2 diabetes associated with attitudes and self-management over time? Diabetes Educ. 2010 Sep-Oct; 36(5):828-34. PMID: 20729511.
      View in: PubMed
    56. Edelman SV, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Chen X, Frias JP. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther. 2010 Aug; 12(8):627-33. PMID: 20615104.
      View in: PubMed
    57. Bailey TS, Edelman SV. Insulin pen use for type 2 diabetes--a clinical perspective. Diabetes Technol Ther. 2010 Jun; 12 Suppl 1:S86-90. PMID: 20515313.
      View in: PubMed
    58. Edelman SV, Bailey TS. Continuous glucose monitoring health outcomes. Diabetes Technol Ther. 2009 Jun; 11 Suppl 1:S68-74. PMID: 19469680.
      View in: PubMed
    59. Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol. 2008 Nov; 2(6):1157-60. PMID: 19885306; PMCID: PMC2769811.
      View in: PubMed, PubMed Central
    60. Edelman SV. Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):194-5. PMID: 18283327.
      View in: PubMed
    61. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008; 22(6):375-86. PMID: 18998755.
      View in: PubMed
    62. Edelman SV. Optimizing diabetes treatment using an amylin analogue. Diabetes Educ. 2008 Jan-Feb; 34 Suppl 1:4S-10S. PMID: 18268000.
      View in: PubMed
    63. Choe C, Edelman SV. The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia. South Med J. 2007 Nov; 100(11):1123-31. PMID: 17984745.
      View in: PubMed
    64. Frias JP, Edelman SV. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes. 2007 Aug; 14(4):269-76. PMID: 17940451.
      View in: PubMed
    65. Edelman SV, Garg S, Kolterman OG. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2. PMID: 17452962.
      View in: PubMed
    66. Edelman S, Dailey G, Flood T, Kuritzky L, Renda S. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care. 2007 Apr 20; 1:9. PMID: 17448241; PMCID: PMC1885266.
      View in: PubMed, PubMed Central
    67. Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc. 2007 Apr; 99(4):357-60, 363-7. PMID: 17444424; PMCID: PMC2569656.
      View in: PubMed, PubMed Central
    68. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007 Apr; 29(4):650-60. PMID: 17617288.
      View in: PubMed
    69. Raine CH, Schrock LE, Edelman SV, Mudaliar SR, Zhong W, Proud LJ, Parkes JL. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. J Diabetes Sci Technol. 2007 Mar; 1(2):205-10. PMID: 19888408; PMCID: PMC2771463.
      View in: PubMed, PubMed Central
    70. Kruger DF, Aronoff SL, Edelman SV. Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis. Diabetes Educ. 2007 02; 33 Suppl 2:32S-46S; quiz 47S-48S. PMID: 17483531.
      View in: PubMed
    71. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95. PMID: 17003291.
      View in: PubMed
    72. Edelman SV, Caballero L. Amylin replacement therapy in patients with type 1 diabetes. Diabetes Educ. 2006 May-Jun; 32 Suppl 3:119S-127S. PMID: 16751353.
      View in: PubMed
    73. Edelman S. Does a patient-administered titration algorithm of insulin glargine improve glycemic control? Nat Clin Pract Endocrinol Metab. 2006 Feb; 2(2):78-9. PMID: 16932261.
      View in: PubMed
    74. Edelman SV. Incretins: what does the future hold? Diabetes Technol Ther. 2005 Oct; 7(5):809-12. PMID: 16241889.
      View in: PubMed
    75. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005 Oct; 28(10):2543-5. PMID: 16186296.
      View in: PubMed
    76. Edelman SV, Morello CM. Strategies for insulin therapy in type 2 diabetes. South Med J. 2005 Mar; 98(3):363-71. PMID: 15813164.
      View in: PubMed
    77. Edelman SV. Thiazolidinediones. N Engl J Med. 2005 Jan 13; 352(2):205-7; author reply 205-7. PMID: 15651124.
      View in: PubMed
    78. Edelman SV, Morello CM. Hypoglycemia unawareness and type 1 diabetes. South Med J. 2004 Nov; 97(11):1143-4. PMID: 15586620.
      View in: PubMed
    79. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, Henry RR. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab. 2005 Jan; 90(1):352-8. PMID: 15483099.
      View in: PubMed
    80. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry RR, Maisel AS. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004 Sep 01; 44(5):1047-52. PMID: 15337217.
      View in: PubMed
    81. Davis T, Edelman SV. Insulin therapy in type 2 diabetes. Med Clin North Am. 2004 Jul; 88(4):865-95, x. PMID: 15308383.
      View in: PubMed
    82. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar; 27(3):734-8. PMID: 14988294.
      View in: PubMed
    83. Chu NV, Edelman SV. BNP levels to screen for left ventricular dysfunction. Curr Diab Rep. 2004 Feb; 4(1):39-40. PMID: 14764278.
      View in: PubMed
    84. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R, Maisel A. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 2003 Jul; 26(7):2081-7. PMID: 12832317.
      View in: PubMed
    85. Chau DL, Edelman SV, Chandran M. Osteoporosis and diabetes. Curr Diab Rep. 2003 Feb; 3(1):37-42. PMID: 12643144.
      View in: PubMed
    86. Chu NV, Edelman SV. Pramlintide as an adjunct to insulin therapy. Curr Diab Rep. 2003 Feb; 3(1):35-6. PMID: 12685439.
      View in: PubMed
    87. Chandran M, Chu NV, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 2003 Feb; 3(1):43-8. PMID: 12643145.
      View in: PubMed
    88. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5(3):355-63. PMID: 12828817.
      View in: PubMed
    89. Edelman S. Aiming for, believing in, and achieving a target A1c of less than 7. J Am Pharm Assoc (Wash). 2003 Jan-Feb; 43(1):121-2. PMID: 12585763.
      View in: PubMed
    90. Edelman S. Aiming for, believing in, and achieving a target a1c of less than 7. J Am Pharm Assoc (Wash). 2003 Jan; 43(1):121-2. PMID: 23945818.
      View in: PubMed
    91. Edelman SV. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev Cardiovasc Med. 2003; 4 Suppl 6:S29-37. PMID: 14668701.
      View in: PubMed
    92. Edelman SV. Pumps and type 2 diabetes. If you can improve your diabetes control, and if you can accommodate yourself to it, the pump might just be the best diabetes therapy for you. Diabetes Forecast. 2002 Jun; 55(6):62-5. PMID: 14964172.
      View in: PubMed
    93. Edelman SV. Insulin pump therapy versus multiple daily injections. Curr Diab Rep. 2002 Feb; 2(1):47-8. PMID: 15279019.
      View in: PubMed
    94. Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep. 2002 Feb; 2(1):60-6. PMID: 12643124.
      View in: PubMed
    95. Sarno MJ, Bell J, Edelman SV. Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabetes Technol Ther. 2002; 4(6):863-6. PMID: 12614490.
      View in: PubMed
    96. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther. 2002; 4(2):175-89. PMID: 12079621.
      View in: PubMed
    Steven's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (260) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (17) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑